On September 10, 2026 Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, reported the acceptance of an abstract for poster presentation at the 38th Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR) (Free AACR Whitepaper). The EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium will take place in Barcelona, Spain from November 18-20, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Avenzo will present preliminary safety, tolerability, and efficacy results from the ongoing Phase 1 portion of AVENTINE-1, a Phase 1/2 study evaluating AVZO-1418, its potentially differentiated EGFR/HER3 bispecific antibody-drug conjugate.

Details of the poster presentation are as follows:

Abstract: 81
Title: Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors
Poster #: PB-081
Poster Session: Antibody-Drug Conjugates
Date and Time: Wednesday, November 18, 2026, 12:00 to 7:00 p.m. CET
Location: Exhibition Hall

(Press release, Avenzo Therapeutics, SEP 10, 2026, View Source [SID1234670715])